Baird raised the firm’s price target on Soleno Therapeutics (SLNO) to $102 from $72 and keeps an Outperform rating on the shares. The frim raised its target sas the FDA approval of its drug for hyperphagia may transform the PWS landscape.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Aardvark Therapeutics price target raised to $26 from $22 at BofA
- Soleno Stock (SLNO) Soars 32% after FDA Greenlights New Drug
- Closing Bell Movers: Stock futures, Big Three automakers fall on auto tariffs
- Soleno Therapeutics announces FDA approval of VYKAT XR to treat hyperphagia
- Soleno Therapeutics up 35% afterhours following resumption of trading
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue